免责声明 投资有风险，入市需谨慎。本内容不构成任何投资建议。投 资者不应以该等信息取代其独立判断或仅根据该等信息做出 决策。申万宏源对这些信息的准确性或完整性不作保证，亦 不对因使用该等信息而引发或可能引游躲损豢秃拐չ-α葛磊 ● 星期一 10月 今日申 ... 今日中签缴 ... <> 股 丰倍生物 732334 团 国 24.49 发行/行业市盈率 30.47/64.73 申购上限 1.1万股 发行价(元) 今日无新债 ...

Group 1: New Stock Listings - Two new stocks were listed in the A-share market last week: Kema Polo and Chaoying Electronics, with Chaoying Electronics seeing a nearly 400% increase on its first day, yielding over 40,000 yuan in profit per subscription [1] - This week, three new stocks are available for subscription: Fengbei Biological, Delijia, and Zhongcheng Consulting, with subscription dates on Monday and Tuesday [1] Group 2: Fengbei Biological - Fengbei Biological is a leading domestic company in the comprehensive utilization of waste oil resources, focusing on the production of biofuels and biobased materials [2] - The company’s IPO price is set at 24.49 yuan per share, with a maximum subscription limit of 11,000 shares per account, requiring a market value of 110,000 yuan [1][2] - Projected revenues for 2022 to 2024 are 1.709 billion yuan, 1.728 billion yuan, and 1.949 billion yuan, with net profits of 133 million yuan, 130 million yuan, and 124 million yuan respectively [2] Group 3: Delijia - Delijia specializes in the research, production, and sales of high-speed heavy-duty precision gear transmission products, primarily for wind power generation [3] - The IPO price is set at a maximum subscription limit of 9,500 shares, requiring a market value of 95,000 yuan [3] - Projected revenues for 2022 to 2024 are 3.108 billion yuan, 4.442 billion yuan, and 3.715 billion yuan, with net profits of 540 million yuan, 634 million yuan, and 534 million yuan respectively [4] Group 4: Zhongcheng Consulting - Zhongcheng Consulting focuses on providing engineering consulting services, including cost estimation, bidding agency, project supervision, and management [5] - The IPO price is set at 14.27 yuan per share, with a maximum subscription limit of 630,000 shares [5] - Projected revenues for 2022 to 2024 are 303 million yuan, 368 million yuan, and 396 million yuan, with net profits of 64 million yuan, 81 million yuan, and 105 million yuan respectively [5][6]

Group 1: New IPOs - Three new stocks are scheduled for subscription this week (October 27 to 31), including two on the Shanghai Stock Exchange and one on the Beijing Stock Exchange [1] - The Shanghai Stock Exchange new stock Fengbei Biological has an issue price of 24.49 CNY per share and a price-to-earnings ratio of 30.47, compared to the industry average of 51.49 [2] - The other Shanghai Stock Exchange new stock Delijia has an issue price of 18.81 billion CNY and is a leader in high-load precision gear transmission products, with a global market share of 10.36% and a domestic market share of 16.22% [3] Group 2: Company Profiles - Fengbei Biological focuses on the comprehensive utilization of waste resources, particularly waste oil, and has developed a production chain from waste oil to biodiesel and bio-based materials [2][3] - Delijia specializes in the research, production, and sales of high-load precision gear transmission products, primarily for wind power applications, and has established deep cooperation with leading clients [3] - Hongban Technology, which is set to go public on October 31, specializes in the research, production, and sales of printed circuit boards, targeting high-end applications and holding a significant market position in consumer and automotive electronics [4] Group 3: Fundraising Goals - Fengbei Biological aims to raise 879 million CNY for projects including the production of 30,000 tons of oleic acid methyl ester and 5,000 tons of biodiesel [3] - Delijia plans to raise 1.881 billion CNY for projects including the production of large onshore and offshore wind turbine gearboxes [3] - Hongban Technology intends to raise 2.057 billion CNY for a project to produce 1.2 million square meters of high-precision circuit boards [4]

Core Insights - The average first-day increase for two new stocks last week was 263%, with Chaoying Electronics rising nearly 400% and a single subscription yielding approximately 34,000 yuan [1] - Three new stocks are scheduled for subscription this week, indicating ongoing market activity despite potential short-term fluctuations [3] Group 1: New Stock Offerings - Fengbei Biological, scheduled for subscription on October 27, is a leading company in the comprehensive utilization of waste oil resources, with significant partnerships in the biofuel sector [1][4] - Delijia, set for subscription on October 28, is a global leader in wind turbine main gearbox supply, with a projected global market share of 10.36% in 2024, ranking third globally [2][5] Group 2: Financial Projections - Fengbei Biological expects a net profit of 106 million to 116 million yuan for the first three quarters of 2025, representing a year-on-year growth of 22.29% to 33.82% [4][5] - Delijia anticipates a net profit of 582 million to 635 million yuan for the first three quarters of 2025, with a year-on-year increase of 52.37% to 66.27% [7][5] - Zhongcheng Consulting projects a net profit of 70 million to 72 million yuan for the first three quarters of 2025, with a slight decline compared to the previous year [8]

Group 1: Market Overview - The average first-day increase for two new stocks this week was 263%, with Chaoying Electronics rising nearly 400%, resulting in a profit of approximately 34,000 yuan per subscription [1] - Short-term market sentiment may experience fluctuations due to the upcoming holiday and the ongoing third-quarter report disclosures, but the medium to long-term bullish atmosphere remains intact [1] Group 2: Upcoming IPOs - Three new stocks are scheduled for subscription next week, including two on the Shanghai Stock Exchange and one on the Beijing Stock Exchange [3] - Fengbei Biological, set to be subscribed on October 27, is a leading company in the comprehensive utilization of waste oil resources, with significant partnerships in the biofuel sector [1][5] - Delijia, scheduled for subscription on October 28, is a global leader in wind turbine main gearbox supply, with a projected global market share of 10.36% in 2024 [2] Group 3: Company Financials - Fengbei Biological expects a net profit of 106 million to 116 million yuan for the first three quarters of 2025, representing a year-on-year growth of 22.29% to 33.82% [5][6] - Delijia anticipates a net profit of 582 million to 635 million yuan for the first three quarters of 2025, indicating a growth of 52.37% to 66.27% [7] - Zhongcheng Consulting projects a net profit of 70 million to 72 million yuan for the first three quarters of 2025, reflecting a slight decline compared to the previous year [9][10]

Group 1: New IPOs Overview - Three new stocks are available for subscription next week, including Fengbei Biological, Zhongcheng Consulting, and Delijia [2] - Fengbei Biological has an issuance price of 24.49 CNY per share and a P/E ratio of 30.47, significantly lower than the industry average of 64.73 [4][10] - Zhongcheng Consulting has an issuance price of 14.27 CNY per share and a P/E ratio of 9.69, compared to the industry average of 40.16 [10] Group 2: Fengbei Biological - Fengbei Biological is a leading company in the comprehensive utilization of waste oil resources, focusing on a production chain from waste oil to biofuels and biobased materials [3][4] - The company reported revenues of 1.709 billion CNY in 2022, with a slight increase to 1.728 billion CNY in 2023, and projected revenues of 1.948 billion CNY for 2024 [5] - For the first half of 2025, Fengbei Biological expects revenues between 2.1 billion CNY and 2.3 billion CNY, representing a year-on-year growth of 51.40% to 65.82% [8] Group 3: Zhongcheng Consulting - Zhongcheng Consulting is an early player in the engineering consulting sector, providing comprehensive consulting services including cost estimation and project management [11] - The company has a significant reliance on clients within Jiangsu Province, with over 96% of its revenue coming from this region from 2022 to 2025 [11] - Revenue figures for Zhongcheng Consulting show a growth from 303 million CNY in 2022 to 368 million CNY in 2023, with a projected revenue of 396 million CNY for 2024 [11] Group 4: Delijia - Delijia is a leading company in the wind power industry, specializing in the research, production, and sales of precision gear transmission products [18] - The company reported revenues of 3.108 billion CNY in 2022, with a decline to 4.442 billion CNY in 2023, and a projected revenue of 3.715 billion CNY for 2024 [18] - For the first half of 2025, Delijia expects revenues between 3.938 billion CNY and 4.073 billion CNY, indicating a year-on-year growth of 61.39% to 66.92% [20]

投资有风险，入市需谨慎。本内容不构成任何投资建议。投 资者不应以该等信息取代其独立判断或仅根据该等信息做出 决策。申万宏源对这些信息的准确性或完整性不作保证，亦 不对因使用该等信息而引发或可能引游躲损豢秃拐չ-α葛磊 III = 星期五 10月 今日申 .. 今日中签缴... 0 <1 股 大明电子 732376 团 国 申购指南 > 12.55 发行/行业市盈率 17.97/30.42 申购上限 0.95万股 发行价(元) 今日无新债 ● 免责声明 ...

Group 1: Company Overview - Taika Ying is the first company in the tire segment of the mining and construction industry to be listed on the Beijing Stock Exchange, recognized as the "first tire stock of the Beijing Stock Exchange" [2] - The company specializes in engineering radial tires and all-steel truck tires, holding a leading position in the engineering radial tire sector, ranking 3rd among Chinese brands and 8th globally in 2023 [3] - Taika Ying has established partnerships with major global and domestic construction machinery manufacturers, including SANY Group, XCMG, Liebherr, and JCB, among others [3] Group 2: Financial Performance - In 2024, Chaoying Electronics reported a main business revenue of 3.945 billion yuan, ranking 41st among global PCB manufacturers with a market share of 0.75% [5] - The company ranks 23rd among comprehensive PCB companies in China, with a market share of 1.41% in mainland China [5] - Chaoying Electronics is recognized as one of the top ten automotive electronic PCB suppliers globally and among the top five in China [5] Group 3: Market Position and Risks - Taika Ying's market share in the domestic engineering radial tire supporting market ranks 3rd among all tire brands, with the highest market share in the domestic market for large-tonnage crane tires [3] - Chaoying Electronics has a stable collaboration with Tier 1 automotive suppliers and well-known electric vehicle manufacturers like Tesla [4] - Both companies face risks related to their operational models, with Taika Ying relying on an outsourcing production model and Chaoying Electronics being sensitive to macroeconomic fluctuations and downstream market demand [4][5]

Core Viewpoint - The article discusses the recent IPO activities in the Chinese stock market, highlighting the significance of the subscription process and the expected performance of new stocks, particularly focusing on Dana Biotechnology and Zhongcheng Consulting. Group 1: IPO Performance - Dana Biotechnology's subscription is noted to be relatively easy but significant, with results expected to provide important reference for future subscriptions, especially for fractional shares [1] - Marco Polo's stock debuted with a significant opening increase of 140.73%, closing with a rise of 128.80% at 31.46 yuan, with a total trading volume of 75.7042 million shares and a turnover of 2.582 billion yuan, indicating a high turnover rate of 77.36% [1] - A single subscription for Marco Polo could yield a profit of 8,855 yuan [1] Group 2: Upcoming IPOs and Subscription Details - Dapeng Industrial, a leading manufacturer in precision cleaning equipment, is set to raise approximately 129 million yuan through its IPO [1] - Zhongcheng Consulting is expected to issue up to 14 million shares, with around 12.6 million shares available for online subscription after accounting for a 10% reduction [4] - The estimated subscription amount for Zhongcheng Consulting is projected to be between 720 billion to 730 billion yuan, indicating a high demand for shares [5] Group 3: Subscription Requirements - The top subscription limit for Zhongcheng Consulting is estimated at approximately 900.9 million yuan, with a minimum funding requirement of around 579.37 million yuan for the shares [5] - The competition for fractional shares in Zhongcheng Consulting is expected to be intense, with a minimum funding threshold likely starting at 600 million yuan, potentially reaching 650 million yuan [5]

Group 1: Company Overview - Danah Biotechnology, established on March 10, 2014, focuses on early diagnosis of invasive fungal diseases and other pathogenic microorganisms, recognized as a national high-tech enterprise and a key specialized "little giant" enterprise supported by the state [2] - The main products include diagnostic reagents and instruments, with reagents accounting for 90.52% of revenue in 2024, while instruments contribute 6.06% [2] - Danah holds a market share of approximately 30% in China's invasive fungal disease diagnostic reagent market as of 2022 [2] Group 2: Product and Supply Chain - The core raw material for Danah's main product, the (1-3)-β-D-glucan test kit, is horseshoe crab blood, which accounted for 21.34% to 32.57% of revenue from 2022 to June 2025 [3] - Horseshoe crabs are classified as a national second-level protected animal, leading to stricter regulations on their utilization, creating uncertainty regarding future supply [3] - Danah has sufficient inventory of horseshoe crab blood to meet production needs for over five years and has begun exploring overseas procurement channels [3] Group 3: Market Position and Financial Performance - Marco Polo, a leading manufacturer and seller of building ceramics, has production bases in multiple locations, with revenues of 8.661 billion, 8.925 billion, and 7.324 billion from 2022 to 2024 [4] - The company ranks first in the domestic building ceramics industry in terms of revenue from 2022 to 2024, indicating strong market presence [4] - Marco Polo's sales model includes both distribution and direct sales, with a significant portion of revenue coming from glazed tiles, which have seen an increasing trend in sales [4][6] Group 4: Revenue Trends and Risks - Marco Polo's main business revenue is projected to decline by 17.95% in 2024 compared to 2023, attributed to changing consumer preferences towards glazed tiles [6] - The company faces potential risks related to fluctuations in the real estate market, which is closely tied to its industry, as indicated by a declining real estate development prosperity index from 2022 to 2024 [6] - Marco Polo also highlights risks associated with raw material and energy price volatility, which could significantly impact profitability if costs cannot be passed on to customers [7]